- Home
- About
- 🤖 AskAnzal AI Advisor
- 📅 Book a Call
- Your Account
- My AskAnzal Account
Over 2,000 real rulings — analysed for what they mean to your team. Published every day.
Showing 1914 cases
PMCPA Director case on clinical trial disclosure for Picato involving Leo. Ruled no breach because the matter was outwith the scope of…
Anonymous complaint about a meeting advertised on LinkedIn. PMCPA concluded no breach because the matter was outwith the scope of the ABPI…
A GP alleged Pfizer’s BMJ Rapid Response was disguised promotion of Lipitor and should include PI and AE reporting. The Panel found…
Servier’s Protelos promotion was challenged over “first/only dual action” claims. Panel found claims misleading, but the Appeal Board ruled the statements of…
BMS alleged Novartis used the ENACT nilotinib expanded access programme and website as disguised promotion of an unlicensed medicine. The Panel found…
Takeda’s Competact mailer claimed it was uniquely cheaper than its constituent parts. After a January Drug Tariff change, Avandamet was also cheaper,…
GSK’s HCP webinar registration page about fluticasone furoate was deemed promotional for Relvar Ellipta but omitted prescribing information. Breach of Clauses 4.1,…
Ivax cited an Italian carbocysteine lysine study (Fluifort) to support Mucodyne COPD claims. The Panel said the products/dosing weren’t shown comparable, so…
A GP received a Univadis mailing containing username/password in an envelope not marked confidential, despite asking to deregister. Panel found no breach…
Complaint about Daily Telegraph articles referencing Victoza. PMCPA found the matter outwith the scope of the ABPI Code; no breach was recorded.…
Complaint about alleged promotion of Cialis. PMCPA recorded no breach because the matter was outwith the scope of the Code; no case…
CCG alleged a Novo Nordisk rep asked a receptionist to add a handwritten Victoza claim about use at eGFR <15. Panel found…
A Pulse ad for fluoxetine used the broad claim “for treatment of depressive illness”. PMCPA ruled it didn’t accurately reflect the SPC…
Vifor’s reps used materials implying Ferinject had fewer ADRs than Monofer. A follow-up “medical information” email was ruled promotional, misleading and disparaging.…
A global Ipsen LinkedIn post featuring a UK-based employee quote linked to an ENGAGE study press release. PMCPA said this brought the…
Anzal, our PMCPA rulings expert, has knowledge of over 2,000 published cases — ask about precedents, clauses, and how they apply to your situation.
One real case. One key lesson. Every week — free.